MedTrace Logo

A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer

NCT03829345 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2019-07-08

No results posted yet for this study

Summary

SOlar is a multi-centre phase II clinical trial of single agent olaparib in advanced oesophagogastric cancer.

Conditions

  • Oesophageal Cancer
  • Gastro-Oesophageal Junction Cancer
  • Gastric Cancer

Interventions

DRUG

Olaparib

Patients will be administered olaparib orally twice daily (BD) at 300mg continuously for each 28 day cycle.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Royal Marsden NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Doctor Starling · Royal Marsden NHS Foundation Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-02
Primary Completion
2021-02-14
Completion
2022-02-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03829345 on ClinicalTrials.gov